The purchase price of
In operation since 1994,
"We are very pleased with this acquisition, which is in line with LSL Pharma's growth strategy of diversifying our service offering and increasing our contract manufacturing operations to better serve the pharmaceutical sector," says
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents.
Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
ABOUT LSL PHARMA GROUP INC.
ABOUT VIRAGE SANTÉ INC.
For more information on the company, please visit www.viragesante.com.
Neither
![](https://ml.globenewswire.com/media/YWIzYzM3MjAtOTc0Ni00NjE3LWI1M2QtOTY4MmFiY2JkMGE0LTEyMTczNTQ=/tiny/LSL-Pharma-Group-Inc-.png)
CONTACTFrançois Roberge President and Chief Executive Officer (514) 664-7700 E-mail: Investors@groupelslpharma.com ORLuc Mainville Executive VP & Chief Financial Officer (514) 664-7700 ext.: 301 E-mail : lmainville@groupelslpharma.com
2024 GlobeNewswire, Inc., source